POWER-remote Weight Loss Program in Early Stage Breast Cancer

Status Completed

Clinical Trial Summary

This research is being done to assess the effectiveness of a weight loss program in women with early stage breast cancer whose body mass index (BMI) is in the overweight or obese range (>25). Weight loss is beneficial in improving cardiovascular risk factors and overall health, but may also decrease the chance of breast cancer coming back. A weight loss counseling program was studied in a general population and was found to be effective to help reduce weight over a 2 year period.

The main goal of this study is to determine if women with a recent diagnosis of early breast cancer will also lose weight with this program. To better understand the effect that weight loss has on women with breast cancer, we will compare the patterns in blood and breast tissue samples (tissue biopsies will be optional), and questionnaires evaluating different aspects of one's well-being, before and after a dietary intervention or no intervention.

Clinical Trial Description

The prevalence of obesity has increased rapidly in recent years. Epidemiological studies since the 1970's have strongly suggested that excess body weight gain may be a major risk factor for many cancers including breast cancer. In addition, once diagnosed with breast cancer, women who are overweight or obese experience worse outcomes despite standard local and adjuvant therapy. Furthermore, most women gain weight following a diagnosis of breast cancer, and this weight gain may increase risk of recurrence by 40-50% and breast cancer-related mortality by 53-60%.

A great deal of effort has been made for many years to explain the relationship between obesity and breast cancer. Molecularly, the relationship involves dynamic and complex interactions between a milieu of hormones, cytokines, adipokines, affecting cell signaling and potentially epigenetic pathways. Recently, studies in postmenopausal women have shown that weight loss modulates these cytokines and adipokines favorably. Inflammation associated with obesity can also be characterized pathologically when macrophages surround necrotic adipocytes in what are called crown-like structures (CLS). Furthermore, increased central obesity as measured by waist-to-hip ratios, may be associated with hypermethylation of certain breast cancer genes, and physical activity can reduce methylation of certain breast cancer-associated genes.

The Women's Intervention Nutrition Study (WINS) demonstrated that women with early-stage breast cancer receiving conventional cancer management randomized to a dietary intervention group had lower risk of relapse compared to those in a control group in those who lost weight. While women with a diagnosis of breast cancer are therefore recommended to maintain ideal body weight, limited progress has been made in developing feasible weight loss programs. However, collaborators from the Welch Center for Prevention, Epidemiology, and Clinical Research at the Johns Hopkins University have recently reported impressive and sustained weight loss in randomized controlled trials designated Practice-based Opportunities for Weight Reduction (POWER) in obese women with at least one cardiovascular risk factor using a remote-support weight loss intervention.

The overall goal of this study is to determine the effectiveness of the remote-support weight loss intervention of the POWER study, designated POWER-remote, in women with early breast cancer who are overweight or obese, and to assess the effects of weight loss of ≥5% body weight at 6 months and on biomarkers associated with obesity, inflammation, and breast cancer. The data will be used to implement a clinical intervention available to all overweight and obese women with breast cancer, and to design definitive studies assessing the impact of weight loss and biomarker modulation on risk of recurrent disease or development of new primary breast cancers. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT01871116
Study type	Interventional
Source	Sidney Kimmel Comprehensive Cancer Center
Contact
Status	Completed
Phase	N/A
Start date	July 2013
Completion date	December 2016

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT02816164` - A Study to Compare Administration Schedules of G-CSF (Filgrastim) for Primary Prophylaxis of Febrile Neutropenia	Phase 4
Completed	`NCT02816112` - Granulocyte-colony Stimulating Factors or Antibiotics for Primary Prophylaxis for Febrile Neutropenia	Phase 4
Completed	`NCT03946683` - Cyberknife for Early Stage Breast Cancer	N/A
Recruiting	`NCT04458532` - Exercise Therapy to Improve Cardiovascular Health in Post-Menopausal Women After Treatment for Early Stage Breast Cancer	N/A
Completed	`NCT01162200` - Cyberknife® Partial Breast Irradiation (PBI) for Early Stage Breast Cancer	Phase 1
Completed	`NCT01965522` - Anti-proliferative Effects of Vitamin D and Melatonin in Breast Cancer	Phase 2
Completed	`NCT00309569` - Randomized Study Comparing Pre- and Postoperative vs. Conventional Adjuvant Treatment in Receptor-negative Patients	Phase 3
Terminated	`NCT01545648` - Pilot Study to Evaluate the Impact of Denosumab on Disseminated Tumor Cells (DTC) in Patients With Early Stage Breast Cancer	Phase 2
Completed	`NCT02428114` - A Multi Centre Study to Determine the Feasibility of Using an Integrated Consent Model to Compare Standard of Care Administration Schedules of G-CSF (Filgrastim) for Primary Prophylaxis of Chemotherapy-Induced Febrile Neutropenia in Early Stage Breast Cancer (React-G Study)	N/A
Active, not recruiting	`NCT02685332` - Phase I Dose Escalation of Single Fraction Adjuvant Stereotactic Body Partial Breast Irradiation Early Stage Breast CA	Phase 1
Completed	`NCT02159157` - A Randomized, Controlled Trial to Determine the Effects of an Exercise Intervention on Physical Activity During Chemotherapy for Patients With Early Stage Breast Cancer	N/A
Terminated	`NCT01166581` - Impact of Breast Magnetic Resonance Imaging (MRI) on Mastectomy Rates	N/A
Recruiting	`NCT06311357` - Percent Weight Change in the Medical Supplement Group of Early Breast Cancer	N/A
Terminated	`NCT02364960` - Targeted Intraoperative Therapy Registry at Bethesda North Hospital (TARGIT)
Active, not recruiting	`NCT03561454` - A Registry of Intra-Operative Radiation Therapy (IORT) Using the Xoft ® Axxent ® eBx ™ System Patients
Completed	`NCT02485678` - A Pragmatic Trial of Ambulatory Toxicity Management in Patients Receiving Adjuvant or Neo-adjuvant Chemotherapy for Early Stage Breast Cancer	N/A
Active, not recruiting	`NCT02297672` - Partial Breast Irradiation Using Interstitial Permanent Palladium-103 Seed Implant	N/A
Completed	`NCT02335671` - Evaluating Mass Spectrometry And Intraoperative MRI In The Advanced Multimodality Image Guided Operating Suite (Amigo) In Breast-Conserving Therapy	N/A
Completed	`NCT03102307` - Registry Trial to Evaluate the Clinical Utilization of Targeted Axillary Dissection (TAD)
Recruiting	`NCT04607473` - ABUS for Early-stage Breast Cancer	N/A